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Introduction: RANKL is important in mammary gland development during pregnancy and mediates the initiation
and progression of progesterone-induced breast cancer. No clinical data are available on the effect of pregnancy
on RANK/RANKL expression in young breast cancer patients.
Methods: We used our previously published dataset of 65 pregnant and 130 matched young breast cancer
patients with full clinical, pathological, and survival information. 85% of patients had available transcriptomic data as
well. RANK/RANKL expression by immunohistochemistry using H-score on the primary tumor and adjacent normal
tissue was performed. We examined the difference in expression of RANK/RANKL between pregnant and non-pregnant
patients and their association with clinicopathological features and prognosis. We also evaluated genes and pathways
associated with RANK/RANKL expression on primary tumors.
Results: RANKL but not RANK expression was more prevalent in the pregnant group, both on the tumor and adjacent
normal tissue, independent of other clinicopathological factors (both P <0.001). 18.7% of pregnant and 5.3% of
non-pregnant patients had tumors showing ≥10% of cells with 3+ RANKL expression. RANKL expression was
significantly higher in progesterone receptor-positive, and luminal A-like tumors, with negative correlation with Ki-67
(all P <0.001). On the contrary, RANK expression was higher in triple negative tumors (P <0.001). Using false discovery
rate <0.05, 151 and 1,207 genes were significantly correlated with tumor-expressed RANKL and RANK expression by
immunohistochemistry, respectively. High RANKL expression within primary tumor was associated with pathways
related to mammary gland development, bone resorption, T-cell proliferation and regulation of chemotaxis, while RANK
expression was associated with immune response and proliferation pathways. At a median follow-up of 65 months,
neither RANK nor RANKL expression within tumor was associated with disease free survival in pregnant or non-pregnant
group.
Conclusions: Pregnancy increases RANKL expression both in normal breast and primary tumors. These results could
guide further development of RANKL-targeted therapy.Introduction
Receptor activator for nuclear factor κB ligand (RANKL)
is a key factor in bone resorption. It binds to receptor
activator for nuclear factor κB (RANK) on the osteoclast
to promote osteoclastogenesis, which results in bone de-
struction, osteoporosis and osseous metastasis [1]. Target-
ing the RANK/RANKL pathway emerged as a rational* Correspondence: hatem.azim@bordet.be
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unless otherwise stated.strategy to arrest this process, and the anti-RANKL mono-
clonal antibody denosumab is currently approved in man-
aging osteoporosis and preventing skeletal-related events
secondary to bone metastases [2,3].
Moreover, RANKL and its receptor have been shown
to play a pivotal role in mammary gland development
and in the increase of mammary stem cell pool during
pregnancy [4]. Preclinical studies showed that RANKL is
a major paracrine effector of progesterone’s mitogenic
action in the mammary epithelium [5,6]. More recently,
data in humans suggested that RANKL expression fluc-
tuates with serum progesterone, both on normal and
malignant breast tissue [7]. Increased mammary tumorhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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function in RANK following pregnancy or in wildtype
mice following treatment with progesterone, a process
that was arrested using a RANKL inhibitor [6]. Further-
more, RANKL was shown to be vital in mediating distant
metastasis in breast cancer mice models [6,8]. Together,
this evidence points to a fundamental role of RANK/
RANKL signaling in breast carcinogenesis.
Breast cancer arising at a young age is known to be
biologically distinct, yet little progress has been made in
identifying potential treatment targets [9]. Previous analysis
by our group has suggested an association between breast
cancer arising at young age and high RANKL mRNA
expression [10]. On the other hand, young women are at a
higher risk of breast cancer shortly after pregnancy and
pregnancy-associated breast cancer is known to have poor
prognosis [11,12]. While preclinical data have suggested a
potential role of RANKL in mediating cancer initiation and
progression associated with pregnancy [4], supporting
clinical data in pregnant cancer patients are lacking.
In the current study, we evaluated for the first time the
expression of RANK and RANKL using immunohisto-
chemistry in young and pregnant breast cancer patients.
Based on preclinical observations, we hypothesized that
pregnancy would increase RANKL expression. We also
evaluated gene expression patterns and activated pathways
associated with RANK and RANKL expression.
Methods
Study population
A total of 195 patients with primary breast cancer were
included in this analysis, of whom 65 were diagnosed
during pregnancy. All patients were diagnosed and man-
aged at the European Institute of Oncology (IEO) in Milan
from 1996 to 2010. Information on the patient’s character-
istics and outcome was published previously [13]. Briefly,
each pregnant patient was matched to two nonpregnant
breast cancer patient controls according to age, tumor size,
nodal status, date of diagnosis and whether neoadjuvant
therapy was administered. All patients provided their
consent to use their tissue samples for research purposes as
per the IEO institutional policies. The study of biological
features including genomic analysis was approved by the
Ethics Committee of Institut Jules Bordet (Number 1782).
Immunohistochemical staining
Formalin-fixed tissues of primary breast surgeries were
used for RANK and RANKL evaluation. For each patient, a
hematoxylin and eosin-stained slide along with representa-
tive slides of the primary tumor and adjacent normal tissue
(>1 cm from tumor) were shipped to Amgen Laboratories
(Seattle, WA, USA) for immunohistochemical staining of
RANK (N-1H8) and RANKL (M366) as described
previously [14,15], blinded to clinical information.For each epitope, the staining score for tumor cells and
adjacent normal epithelial cells was recorded separately.
The percentage of immunostaining and the staining inten-
sity (0, negative; 1+, weak; 2+, moderate; and 3+, strong)
were recorded. An H-score was calculated using the
following formula:
H‐score ¼ % of cells of weak intensity  1ð Þ
þ percentage of cells of moderate intensity  2ð Þ
þ percentage of cells of strong intensity  3ð Þ
The maximum H-score would be 300, corresponding
to 100% of cells with strong intensity.
Evaluation of the histological subtype, histological
grade and conventional breast cancer markers including
estrogen receptor (ER), progesterone receptor (PgR), hu-
man epidermal growth factor receptor 2 (HER2) and Ki67
were performed at IEO. Breast cancer subtypes were de-
fined using immunohistochemical surrogates as follows:
luminal A like – ER and/or PgR(+), HER2(–), Ki67 < 20%;
luminal B like – ER and/or PgR(+), HER2(–), Ki67 ≥ 20;
triple negative – ER, PgR and HER2(–), irrespective of
Ki67 score; and HER2 – HER2(+), irrespective of ER, PgR
or Ki67.
Gene expression profiling
Gene expression profiling using Affymetrix on the primary
tumors of 85% of the included patients was published pre-
viously [16] and is publically available on Gene Expression
Omnibus [GEO:GSE53031] [17].
To evaluate gene expression differences according to
RANK and RANKL expression, we performed a linear
regression model – testing genes that are associated with
RANK, RANKL H-score; all treated as continuous
variables. To control for multiple testing, we used the false
discovery rate approach [18]. Genes presenting false
discovery rate <0.05 were considered significantly
associated with RANK or RANKL expression. We used a
gene-set enrichment analysis (GSEA) to evaluate pathways
associated with RANK or RANKL expression using the
hypergeometric probabilities as published previously [19].
Statistical analyses
We evaluated the difference in expression of RANK/
RANKL H-score tested as a continuous variable on tumor
and adjacent normal tissue between pregnant and nonpreg-
nant patients. We also evaluated correlations between
RANK/RANKL expression and the variables tumor size,
nodal status, ER, PgR, HER2, Ki67 and breast cancer
subtype using the Pearson chi-squared test. To evaluate
factors that were independently associated with RANK/
RANKL expression, a linear regression model was
constructed including all of the aforementioned variables.
We evaluated the association between tumor RANK and
RANKL expression as a continuous variable and disease-
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pregnant and all patients combined.
Analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC, USA) and R version 2.12.2 [20]. All
tests were two-sided.
Results
Table 1 summarizes the patients’ characteristics. As re-
ported previously [13], no differences in clinicopatholog-
ical features or breast cancer subtypes were observed
between pregnant and nonpregnant patients. The median
age was 36 years (range: 26 to 48 years). Information on
prior parity and menstrual status at tumor sampling was
not available.
RANK and RANKL expression by immunohistochemistry
and association with pregnancy and clinicopathological
features
RANKL staining was performed on 194 primary tu-
mors (99%) and 176 adjacent normal tissues (90%); the
results were positively correlated (r = 0.38, P < 0.001).Table 1 Patient characteristics and association with RANK and
Pregnant (n = 65) Nonpregnant (n = 13
Tumor size
≤ 2 cm 26 (40%) 52 (40%)
> 2 cm or pTxb 38 (60%) 78 (60%)
Nodal status
Negative 28 (43.1%) 56 (43.1%)
Positive or pNxb 37 (56.9%) 74 (56.9%)
Histological gradec
I 4 (6.2%) 4 (3.1%)
II 21 (32.3%) 43 (33.1%)
III 36 (55.3%) 68 (52.3%)
ER
Positive 43 (66.1%) 96 (73.8%)
Negative 22 (33.9%) 34 (26.2%)
PgR
Positive 42 (64.6%) 85 (65.4%)
Negative 23 (35.4%) 45 (34.6%)
HER2
Positive 11 (16.9%) 23 (17.7%)
Negative 54 (83.1%) 107 (82.3%)
PIK3CA mutationd
Yes 10 (15.4%) 27 (20.7%)
No 52 (84.7%) 102 (79.3%)
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progeste
activator for nuclear factor κB ligand. aNot assessable in one patient in the pregnant g
pathological nodal status is not evaluable (pNx) (two pregnant and four nonpregnant)
assessable in four patients (one pregnant and three nonpregnant). pTx (pathological tuThe mean RANKL expression on normal epithelial
cells was higher compared with that on tumor cells
(50.19 vs. 16.13, P <0.001) (Figure 1a). Patients diag-
nosed during pregnancy had significantly higher RANKL
expression both on tumor cells (32.53 vs. 8.06, P <0.001)
and adjacent normal tissue (87.29 vs. 32.88, P <0.001)
(Figure 1a). In total, 18.7% of pregnant patients and 5.3%
of nonpregnant patients had ≥10% of cells showing
strong RANKL staining (score 3+) on primary tumor,
while 55.3% and 29.1% of pregnant and nonpregnant
patients had at least 10% of cells 3+ on adjacent normal
tissue (Figure 2a,b). Additional file 1 shows examples of
different staining intensities of RANKL. Among pregnant
patients, a slightly lower expression of RANKL in both
tumor and adjacent normal epithelial cells was observed
in patients diagnosed in the third trimester of pregnancy
(Figure S2a,b in Additional file 2).
RANK staining was performed on all 195 primary tu-
mors and 181 adjacent normal tissue samples (92.8%) and
both results were positively correlated (r = 0.27, P < 0.001).
The mean RANK H-score was higher for normalRANKL expression by immunohistochemistry
0) Mean RANKL H-score on
primary tumor (P value)a
Mean RANK H-score on
primary tumor (P value)
28.21 10.08
8.63 (P = 0.01) 17.50 (P = 0.15)
24.51 14.12
9.04 (P = 0.03) 14.36 (P = 0.96)
70 7.5
29.92 3.82
6.25 (P < 0.001) 22.2 (P < 0.001)
20.43 5.43
5 (P = 0.05) 36.71 (P < 0.001)
24.11 5.09
0.67 (P < 0.001) 31.76 (P < 0.001)
3.18 10.82
18.79 (P = 0.1) 14.95 (P = 0.53)
24.03 6.3
12.47 (P = 0.18) 15.63 (P = 0.13)
rone receptor; RANK, receptor activator for nuclear factor κB; RANKL, receptor
roup. bA total of six patients had pathological tumor size is not evaluable (pTx) or
. cNot assessable in 19 patients (four pregnant and 15 nonpregnant). dNot
mor size is not evaluable) or pNx (pathological nodal status is not evaluable).
Figure 1 Differences in RANK and RANKL expression between pregnant and nonpregnant breast cancer patients. (a) Expression of
RANKL by immunohistochemistry using the H-score (y axis) in all patients, pregnant patients and nonpregnant patients both in primary tumor
(blue) and adjacent normal breast epithelial cells (green). Mean RANKL H-score was higher in normal breast epithelial cells compared with tumor
cells; 50.19 versus 16.13, P <0.001 in all patients; 32.88 versus 8.06, P <0.001 in nonpregnant patients; and 87.29 versus 32.53 in pregnant patients,
P <0.001. (b) Expression of RANK by immunohistochemistry using the H-score (y axis) in all patients, pregnant patients and nonpregnant patients
both in primary tumor (blue) and adjacent normal breast epithelial cells (green). Mean RANK H-score was higher in normal breast epithelial cells
compared with tumor cells; 24.65 versus 12.48, P = 0.003 in all patients; 21.72 versus 13.95, P = 0.07 in nonpregnant patients; and 31.52 versus 9.41
in pregnant patients, P = 0.016. RANK, receptor activator for nuclear factor κB; RANKL, receptor activator for nuclear factor κB ligand.
Figure 2 Examples of RANK and RANKL immunohistochemical staining on primary breast tumors and normal breast tissue. (a) RANKL
expression on the primary tumor in a patient diagnosed with breast cancer during pregnancy (H-score: 270, 80% of cells showing RANKL
expression score 3+). (b) RANKL expression on adjacent normal epithelial cells in a patient diagnosed with breast cancer during pregnancy
(H-score: 265, 80% of cells showing RANKL expression score 3+). (c) RANK expression on the primary tumor in a young breast cancer patient not
diagnosed during pregnancy (H-score: 140, 20% of cells showing RANK expression score 3+). (d) RANK expression on adjacent normal epithelial
cells in a patient diagnosed with breast cancer during pregnancy (H-score: 210, 40% of cells showing RANK expression score 3+). RANK, receptor
activator for nuclear factor κB; RANKL, receptor activator for nuclear factor κB ligand.
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No significant differences in RANK expression were ob-
served between pregnant and nonpregnant patients; either
on tumor tissue (13.74 vs. 14.51, P = 0.88) or adjacent nor-
mal epithelial cells (32.29 vs. 19.78, P = 0.07). Figure 2c,d
shows RANK expression on primary tumor and adjacent
normal tissue. Additional file 3 shows other examples of
different staining intensities of RANK. Among pregnant
patients, a slightly lower RANK expression was observed
in patients diagnosed in the first trimester of pregnancy
(Figure S2c,d in Additional file 2).
Table 1 shows the association between RANK and
RANKL expression on the primary tumor and clinicopath-
ological features. For pregnant and nonpregnant patients,
RANKL expression was higher in small (P = 0.01),
well-differentiated (P <0.001) and PgR-positive tumors
(P <0.001). On the contrary, higher RANK expression was
observed in patients with poorly differentiated andFigure 3 Expression of RANK and RANKL according to breast cancer s
immunohistochemistry using the H-score (y axis) according to breast cance
RANKL expression was higher in luminal A tumors (ER+, HER2–, Ki67 < 20%
(P <0.0001), than in nonpregnant patients (P = 0.32). (b) Negative correlatio
H-score (x axis) (P <0.0001, Pearson correlation = –0.29). (c) Expression of RA
breast cancer subtypes in all patients, nonpregnant patients and pregnant
compared with all other subtypes in all patients (P <0.0001), nonpregnant pat
between Ki67 score by immunohistochemistry (y axis) and RANK H-score (x ax
human epidermal growth factor receptor 2; RANK, receptor activator for nuclehormone receptor-negative tumors (all P <0.001). RANKL
expression was significantly higher in luminal A-like tu-
mors (mean H-score: 45.45) compared with other subtypes,
with the lowest expression observed in triple-negative sub-
types (mean H-score: 0.23) (Figure 3a). Furthermore, the
RANKL H-score was negatively correlated with Ki67
(P < 0.001) (Figure 3b). On the other hand, RANK expres-
sion was significantly higher in triple-negative tumors
(mean H-score: 40.91) with the lowest expression ob-
served in luminal A tumors (mean H-score: 4.68)
(Figure 3c). A positive correlation was observed between
RANK H-score and Ki67 (Figure 3d).
To evaluate factors independently associated with
RANKL and RANK expression, an adjusted linear regres-
sion model showed that only pregnancy and high PgR ex-
pression were independently associated with high tumor
RANKL expression (both P <0.001). On the other hand,
breast cancer subtypes and administering neoadjuvantubtype and correlation with Ki67. (a) Expression of RANKL by
r subtypes in all patients, nonpregnant patients and pregnant patients.
) compared with all other subtypes, particularly in pregnant patients
n between Ki67 score by immunohistochemistry (y axis) and RANKL
NK by immunohistochemistry using the H-score (y axis) according to
patients. RANK expression was higher in triple-negative tumors
ients (P < 0.0001) and pregnant patients (P = 0.05). (d) Positive correlation
is) (P <0.0001, Pearson correlation = 0.37). ER, estrogen receptor; HER2,
ar factor κB; RANKL, receptor activator for nuclear factor κB ligand.
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expression (P <0.001) (Table 2).
Genes and pathways associated with RANK and RANKL
expression on primary breast tumors
Using false discovery rate <0.05, out of 18,665 evaluated
genes 1,207 genes and 151 genes were significantly corre-
lated (either positively or negatively) with RANK and
RANKL H-score, respectively (Additional file 4). Almost
perfect correlation was observed between tumor RANKL
H-score and mRNA levels (r = 0.89, P < 0.001) (Figure 4a).
A weaker correlation, albeit significant, was observed be-
tween tumor RANK H-score and mRNA levels (r = 0.19,
P = 0.012) (Figure 4b). GSEA showed that tumors express-
ing high levels of RANKL by immunohistochemistry had
activated pathways; of particular relevance were those re-
lated to bone resorption, mammary gland development,
regulation of chemotaxis and T-cell proliferation. On the
other hand, high RANK expression was associated with
several activated pathways, of relevance to immune re-
sponse, and proliferation-related pathways (Additional
file 5). These results were consistent even after adjusting
the analysis for pregnancy status.
Association between RANK and RANKL expression on the
primary tumor and disease-free survival
At a median follow-up of 65 months, 41.5% of the preg-
nant patients (n = 27) and 26.1% of the nonpregnant pa-
tients (n = 34) developed a disease-free survival event.
Neither RANK nor RANKL were associated with the
outcome when considering pregnant patients, nonpreg-
nant patients or both groups combined (Additional file 6).
Discussion
This is the first study to evaluate the expression of RANK
and RANKL in young and pregnant breast cancer patients.
We found that pregnancy significantly increases RANKL
expression both on the tumor and adjacent normal epithe-
lial tissue. We also found that RANKL expression isTable 2 Linear regression model showing clinicopathological
RANKL expression
Diagnosis during pregnancy (yes vs. no)
Tumor size (≤2 cm vs. >2 cm)
Nodal involvement (negative vs. positive)
Histological grade (I vs. II vs. III)
Breast cancer subtypes (luminal A vs. luminal B vs. HER2 vs. triple negative)
Increasing progesterone receptor expression by IHC (continuous variable)
Neoadjuvant chemotherapy (yes vs. no)
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; RAN
factor κB ligand.associated with activation of important cancer-related
pathways.
Recently, Pfitzer and colleagues reported on RANK/
RANKL expression in primary breast tumors analyzing 601
core biopsies collected from the neoadjuvant GeparTrio
phase III trial, using the same antibodies and staining pro-
cedures as in the current analysis [14]. However, unlike
our study where we did not use cutoff points to define
RANK/RANKL positivity, Pfitzer and colleagues used an
H-score cutoff value ≥8.5 to define patients with high ex-
pression. In their analysis, high RANK and RANKL ex-
pressions were observed in 14.5% and 6%, respectively. In
the current study, RANK and RANKL H-scores ≥8.5 were
observed in 28.5% and 12.3% respectively in the nonpreg-
nant group and in 18.5% and 29.2% in the pregnant group.
Previously, we reported higher RANKL mRNA expression
in younger breast cancer patients [10]. The higher preva-
lence of RANK/RANKL expression in the current analysis
could be due to the younger patient population in the
current study (median age = 36 years) compared with the
GeparTrio trial (median age = 49 years). It is important to
note that in our analysis, RANK/RANKL expression was
evaluated in surgical specimens as opposed to core biop-
sies (as in the GeparTrio trial). We have shown that both
RANK and RANKL heterogeneously stain tumor and nor-
mal breast tissue (Additional files 1 and 3); therefore, it is
also possible that the small core samples may underrepre-
sent the incidence of RANK and RANKL expression.
We observed higher RANK expression in poorly differ-
entiated and triple-negative tumors, with positive correl-
ation between RANK H-score and Ki67 labeling index.
Similar findings were also observed in the GeparTrio
study and in earlier work using RANK mRNA expression
[14,21]. This is consistent with preclinical work showing
that RANK induces the expression of breast cancer
stem and basal/stem cell markers [21]. On the other
hand, we found higher expression of RANKL in the
slowly proliferating luminal A-like tumors. Positive cor-
relation was observed between RANKL H-score andfactors that are independently associated with RANK and
Independent association
with increasing RANKL
expression (P value)
Independent association
with increasing RANK
expression (P value)
<0.001 0.67
0.23 0.87
0.15 0.19
0.09 0.7
0.75 <0.001
<0.001 0.17
0.69 <0.001
K, receptor activator for nuclear factor κB; RANKL, receptor activator for nuclear
Figure 4 Correlation between RANK and RANKL H-score and mRNA levels. (a) Positive correlation between RANKL mRNA expression (y axis)
and RANKL H-score by immunohistochemistry (x axis) (P <0.0001, Pearson correlation = 0.89). (b) Positive correlation between RANK mRNA expres-
sion (y axis) and RANK H-score by immunohistochemistry (x axis) (P = 0.01, Pearson correlation = 0.19). RANK, receptor activator for nuclear factor
κB; RANKL, receptor activator for nuclear factor κB ligand.
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sistent with the preclinical data showing co-expression of
RANKL and PgR on the normal breast, pre-invasive le-
sions and invasive lesions [6].
The striking difference in RANKL expression between
pregnant and nonpregnant patients is intriguing. RANKL
expression was significantly higher in both the normal epi-
thelial and neoplastic cells arising during pregnancy. These
results are consistent with preclinical data showing high
expression of RANKL in normal breast tissue during preg-
nancy [4]. However, this is the first report to evaluate
RANKL expression in tumors diagnosed during pregnancy
in the clinical setting. We also found that RANK and
RANKL expression differ according to the pregnancy tri-
mester (Additional file 2), which was also observed in pre-
clinical experiments [4].
The gene expression analysis provided confirmatory
data regarding the known functions of RANK and
RANKL and insights into the potential role(s) of RANK
and RANKL in breast carcinogenesis. We observed a
positive correlation between immunohistochemistry and
mRNA expression, confirming the robustness of the per-
formed assays. We also determined significant correl-
ation between the RANKL H-scores and genes known to
be related to RANKL function such as PgR and parathy-
roid hormone-related protein (Figure S5b in Additional
file 7). There was significant correlation between genes
that we recently found to be related to breast cancer
during pregnancy, such as insulin growth factor 1 andTC1 (Figure S5c,d in Additional file 7), a positive regulator
of the Wnt/beta-catenin signaling pathway [16]. Consist-
ent with the known functions of RANKL, we observed
activation of bone resorption and mammary gland devel-
opment pathways in tumors with high RANKL expression.
We also observed high expression of pathways related to
T-cell proliferation. RANKL is known to enhance T-cell
response and increase dendritic cell survival via binding to
RANK [22]. RANKL expression on the tumor was associ-
ated with downregulation of proliferation and cell cycle-
related pathways, which is consistent with the clinical
correlations that we observed, in which high RANKL was
mainly observed in the slowly proliferative tumors. On the
other hand, RANK expression was associated with activa-
tion of immune response and proliferation, again consist-
ent with the high expression of RANK in the poorly
differentiated, triple-negative tumors in which immune-
related pathways are emerging as important targets in this
tumor subtype [23].
A limitation of our study is the small sample size,
which might have masked a potential prognostic role of
RANK or RANKL. Recently, neither was found to be
predictive of pathological complete response in a large
neoadjuvant study [14]. However, irrespective of the
prognostic value of RANK and RANKL, their role as
cancer targets is established. Another limitation is the
lack of information on the phase of menstrual cycle at
the time of tissue sampling, as evolving data suggest
RANKL expression to vary across the menstrual cycle
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in RANKL expression between pregnant and nonpreg-
nant patients are unlikely to be significantly impacted by
the unavailability of these data.
Our results underscore the relevance of RANKL as a
potential target in breast cancer arising in young women.
To further validate this concept, we are conducting a
preoperative window trial evaluating the impact of the
anti-RANKL denosumab on the biology of tumors aris-
ing in young women (D-BEYOND; NCT01864798). We
also found that tumors diagnosed during pregnancy are
more likely to express RANKL, raising the question of
whether it could serve as a valid treatment target in
these patients. To date we lack evidence supporting the
use of denosumab in patients with primary breast can-
cer, yet several studies are currently ongoing to address
this question including the predictive value of RANKL
expression [25]. Another important finding is the high
expression of RANKL in the normal breast of pregnant
patients. Preclinical data support the important role of
RANKL expression in breast cancer initiation, and given
the known short-term risk of developing breast cancer
following pregnancy it is plausible that RANKL expres-
sion on the normal breast would identify patients at high
risk of developing breast cancer following pregnancy.
This hypothesis is rather speculative and requires further
investigation, but could potentially open a new venue for
identifying high-risk women who are candidates for che-
moprevention strategies.
Conclusions
This is the first study to evaluate the expression of
RANKL in young and pregnant breast cancer patients.
Our results indicate that pregnancy significantly increases
RANKL expression independent of PgR or other factors;
both on the primary tumor and on normal breast tissue.
High expression of RANKL is also associated with activa-
tion of important cancer-related pathways. Our findings
confirm the preclinical evidence suggesting RANKL as a
potential breast cancer treatment target; particularly in
young women and pregnancy-associated tumors.
Additional files
Additional file 1: Is Figure S1 showing representative
immunohistochemistry (IHC) images illustrating the range of
staining intensity and heterogeneity expression for RANKL. The
H-score method, as described in Methods, accounts for the heterogeneity
in staining intensity and fraction of cells with any staining observed with
RANKL IHC. Scores were recorded for the percent of cells that stained
with intensity of 0, 1, 2, 3. An H-score was calculated as follows: (% cells
of 1 intensity × 1) + (% cells of 2 intensity × 2) + (% cells of 3 intensity × 3) =
H-score. The maximum H-score would be 100% of cells of intensity 3, which
would be 300. The precise H-score calculation is included for each image of
low-expressing, medium-expressing and high-expressing examples. The
staining score for tumor cells and normal adjacent cells were recordedseparately. Similar heterogeneity in RANKL staining intensity and fraction of
positive cells was observed in both tumors and normal breast. (a) RANKL
IHC of a breast tumor sample with relatively low expression (H-score = 21).
(b). RANKL IHC of a breast tumor sample with medium expression
(H-score = 60). (c). RANKL IHC of a breast tumor sample with high expression
(H-score = 140). (b) and (c) represent the heterogeneous distribution of
RANKL staining intensities within the same sample.
Additional file 2: Is Figure S2 showing (a) RANKL expression by
immunohistochemistry on the primary tumor of pregnant patients
according to trimester at breast cancer diagnosis. y axis, mean
H-score and 95% confidence interval. Tumor diagnosed in the third trimester
had the lowest RANKL expression (trimester 1 + 2 vs. trimester 3, P = 0.04).
(b) RANKL expression by immunohistochemistry on adjacent normal epithelial
cells of pregnant patients according to trimester at breast cancer diagnosis.
y axis, mean H-score and 95% confidence interval. RANKL expression was
lowest in the third trimester (trimester 1 + 2 vs. trimester 3, P < 0.001). (c)
RANK expression by immunohistochemistry on the primary tumor of
pregnant patients according to trimester at breast cancer diagnosis. y axis,
mean H-score and 95% confidence interval. Tumor diagnosed in the first
trimester had the lowest RANK expression (trimester 1 vs. trimester 2 + 3,
P = 0.4). (d) RANK expression by immunohistochemistry on adjacent normal
epithelial cells of pregnant patients according to trimester at breast cancer
diagnosis. y axis, mean H-score and 95% confidence interval. RANK expression
was lowest in the first trimester (trimester 1 vs. trimester 2 + 3, P = 0.27).
Additional file 3: Is Figure S3 showing representative IHC images
illustrating the range of staining intensity and heterogeneity
expression for RANK. IHC scoring was performed using the H-score
method, which accounts for the heterogeneity in staining intensity and
fraction of cells with any staining observed with both RANK and RANKL IHC.
Scores were recorded for the percent of cells that stained with intensity of 0,
1, 2, 3. An H-score was calculated as follows: (% cells of 1 intensity × 1) + (%
cells of 2 intensity × 2) + (% cells of 3 intensity × 3) = H-score. The maximum
H-score would be 100% of cells of intensity 3 which would be 300. The
precise H-score calculation is included for each image of low-expressing,
medium-expressing and high-expressing examples. The staining score for
tumor cells and normal adjacent cells was recorded separately. Similar
heterogeneity in RANK staining intensity and fraction of positive cells was
observed in both tumors and normal breast. (a) RANK IHC of a breast tumor
sample with relatively low expression (H-score = 20). (b). RANK IHC of a
breast tumor sample with high expression (H-score = 70). (c). RANK IHC of a
breast tumor sample with very high expression (H-score = 140). This image
represents RANK expression detection at three different staining intensities
within the same sample.
Additional file 4: Is a table presenting genes associated with RANK
and RANKL expression by immunohistochemistry using the H-score
as a continuous variable.
Additional file 5: Is Figure S4 showing gene-set enrichment analysis
showing upregulated pathways associated with RANKL (a) and
RANK (b) expression by immunohistochemistry using the H-score as
a continuous variable.
Additional file 6: Is a table presenting univariate Cox regression
analysis evaluating the effect of RANKL and RANK expression on
disease-free survival.
Additional file 7: Is Figure S5 showing (a) positive correlation
between PgR mRNA expression (y axis) and RANKL H-score by
immunohistochemistry (x axis) (P <0.0001, Pearson correlation = 0.35).
(b) Positive correlation between parathyroid hormone-related hormone
mRNA expression (y axis) and RANKL H-score by immunohistochemistry
(x axis) (P <0.0001, Pearson correlation = 0.47). (c) Positive correlation between
IGF1 mRNA expression (y axis) and RANKL H-score by immunohistochemistry
(x axis) (P <0.0001, Pearson correlation = 0.34). (d) Positive correlation between
TC1 mRNA expression (y axis) and RANKL H-score by immunohistochemistry
(x axis) (P < 0.0001, Pearson correlation = 0.32).
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